NPPA and neoplasm: In conclusion, aberrant activation of KP as well as a solid correlation between high expression of IDO1 or IDO1/TDO and tumor progression or poor patients’ outcome should be kept in mind when selecting the candidate tumor type for clinical trials of IDO1 inhibitors.